The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.